Is Bravura Solutions Ltd the best software share on the ASX?

Broker gives compelling reasons why Bravura Solutions Ltd (ASX:BVS) could be a good buy.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Provider of software to wealth management and funds administration clients, Bravura Solutions Ltd (ASX: BVS) is in buy territory, according to brokers from investment advisory firm Wilsons, despite its shares hovering around 52-week highs.

It's been a lucrative 12 months for the $668 million market cap company whose products are in use across the Asia-Pacific, Europe, The Middle East and Africa across superannuation, life insurance, private wealth and portfolio administration clients.

Bravura's share price has shot up from $1.36 at this time last year to land at $3.12 at Friday's close – a rise of 129% and not far from Bravura's 52-week high of $3.25 on May 9.

According to Wilsons, who recently visited Bravura in the UK, the company has nothing but positive news on the horizon, with its strong customer pipeline, exposure to the digitisation trend and various regulatory drivers indicating the stock is a buy.

Wilsons believe Bravura is getting things right from an operational perspective, with its improvement of maintenance margins increasing leverage and high recurring revenues giving the broker confidence that FY20 forecasts will increase and although its share price is at a high – the broker believes a current buy in would still be good value.

The broker increased its price target to $3.26 with its key reasons for backing the company including:

  • Margin leverage

Wilsons believe Bravura is becoming less dependent on the timing of its new deals as it begins to grow its product capabilities due in part to a strategic focus by the company on financial organisations, with client-funded research and development providing greater headroom for margin expansion.

  • Pipeline strength

Bravura's Sonata platform has a strong pipeline for growth in particular due to digitisation in the wealth management space with Wilsons forecasting 70% of FY18 revenue will come from Bravura's wealth management platforms.

  • M&A potential

Wilsons has consistently increased its cash flow forecasts on Bravura, believing the company's $24 million cash balance sheet as at the first half of 2018 should drive the potential for merger and acquisition action.

  • Valuation

According to the broker Bravura currently trades on a FY19E 4x EV/ recurring revenue and an EV/EBITDA of 15x vs peers at 12.3x. Wilsons see margin leverage driving a stronger premium on the EV/EBITDA multiple going forward which will contribute to Bravura's potential upside despite the peripheral risks of contract slippage.

Bravura is not the only emerging software player gaining attention for its innovation and early success.

Provider of cloud-based talent management software solutions ELMO Software Ltd (ASX: ELO) is also gaining attention in the tech space – so far outperforming its prospectus forecasts with Morgan Stanley earlier this month placing a $6.30 price target on the stock – which closed off trade on Friday at $5.32.

Another one to watch is the more substantial $5.4 billion market cap online accounting and business services company Xero Limited (ASX: XRO) who nailed the Australia and New Zealand market before expanding into the UK – a move that looks to be tracking well.

Investors are still waiting for Xero to turn a profit, but the likelihood is good, and the company is certainly one to consider in the sector.

Foolish takeaway

Bravura is a high-quality, fast-growing fintech company that just seems to keep kicking goals in the last 18 months. While its share price rise in the last 12-months might mean some investors are reluctant to buy in at these levels, I think its price will continue to go up, so any small dip would be worth consideration if a buy in is on your horizon.

Motley Fool contributor Carin Pickworth has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended ELMOSFTWRE FPO. The Motley Fool Australia owns shares of Bravura Solutions Ltd and Xero. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »